1
|
Guo C, Feng Q, Xie X, Li Y, Hu H, Hu J, Fang S, Shang L. Cross-reaction mediated by distinct key amino acid combinations in the complementary-determining region (CDR) of a monoclonal antibody. J Med Virol 2024; 96:e29430. [PMID: 38285507 DOI: 10.1002/jmv.29430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Revised: 12/27/2023] [Accepted: 01/16/2024] [Indexed: 01/31/2024]
Abstract
In immunology, cross-reaction between antigens and antibodies are commonly observed. Prior research has shown that various monoclonal antibodies (mAbs) can recognize a broad spectrum of epitopes related to influenza viruses. However, existing theories on cross-reactions fall short in explaining the phenomena observed. This study explored the interaction characteristics of H1-74 mAb with three peptides: two natural peptides, LVLWGIHHP and LPFQNI, derived from the hemagglutinin (HA) antigen of the H1N1 influenza virus, and one synthetic peptide, WPFQNY. Our findings indicate that the complementarity-determining region (CDR) of H1-74 mAb comprised five antigen-binding sites, containing eight key amino acid residues from the light chain variable region and 16 from the heavy chain variable region. These critical residues formed distinct hydrophobic or hydrophilic clusters and functional groups within the binding sites, facilitating interaction with antigen epitopes through hydrogen bonding, salt bridge formation, and π-π stacking. The study revealed that the formation of the antibody molecule led to the creation of binding groups and small units in the CDR, allowing the antibody to attach to a variety of antigen epitopes through diverse combinations of these small units and functional groups. This unique ability of the antibody to bind with antigen epitopes provides a new molecular basis for explaining the phenomenon of antibody cross-reaction.
Collapse
Affiliation(s)
- Chunyan Guo
- Central Laboratory of Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China
- Research Center of Cell Immunological Engineering and Technology of Shaanxi Province, Xi'an, Shaanxi, China
- Shaanxi Provincial Key Laboratory of Infection and Immune Diseases, Xi'an, Shaanxi, China
| | - Qing Feng
- Central Laboratory of Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China
- Research Center of Cell Immunological Engineering and Technology of Shaanxi Province, Xi'an, Shaanxi, China
- Shaanxi Provincial Key Laboratory of Infection and Immune Diseases, Xi'an, Shaanxi, China
| | - Xin Xie
- Central Laboratory of Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China
| | - Yan Li
- Central Laboratory of Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China
- Research Center of Cell Immunological Engineering and Technology of Shaanxi Province, Xi'an, Shaanxi, China
- Shaanxi Provincial Key Laboratory of Infection and Immune Diseases, Xi'an, Shaanxi, China
| | - Hanyu Hu
- Shaanxi Ruiqi Biology Sci-Tech Co., Ltd., Xi'an, Shaanxi, China
| | - Jun Hu
- Central Laboratory of Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China
- Research Center of Cell Immunological Engineering and Technology of Shaanxi Province, Xi'an, Shaanxi, China
| | - Senbiao Fang
- Department of Molecular Pharmacology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China
| | - Lijun Shang
- School of Human Sciences, London Metropolitan University, London, UK
| |
Collapse
|